Search clinical trials for: Lanreotide autogel

Total 109 results

Asan Medical Center
Samsung Medical Center; Seoul St. Mary's Hospital; Seoul National University... and other collaborators

Recruiting

Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs (AIM-NETs)

Neuroendocrine Tumors

Korea, Republic of
Sheba Medical Center

Completed

Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy

Congenital Hyperinsulinism

Israel
Ipsen

Active, not recruiting

Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China

Acromegaly

China
Universitaire Ziekenhuizen KU Leuven
Ipsen

Completed

SOMATULINE Autogel 90 mg IN DUMPING SYNDROME

Dumping Syndrome

Belgium
Ipsen

Completed

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs (PALACE)

Gastroenteropancreatic Neuroendocrine Tumor

China
Ipsen

Completed

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome (ELECT)

Carcinoid Syndrome

United States, Turkey, Brazil, India, Ukraine, South Africa, Czechia, Latvia, Poland, Russian Federation, Serbia
Ipsen

Completed

Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma (PRIMARYS)

Acromegaly

Netherlands, Germany, France, United Kingdom, Turkey, Belgium, Czechia, Finland, Italy
Ipsen

Completed

Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour (NET729)

Non Functioning Entero-pancreatic Endocrine Tumour

United Kingdom, France, Spain, United States, Belgium, Czechia, Italy, Slovakia, Poland
Ipsen

Completed

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours (CLARINET)

Endocrine Tumors

United States, United Kingdom, Netherlands, Belgium, Sweden, Spain, France, Denmark, India, Germany, Austria, Czechia, Italy, Poland, Slovakia
Ipsen

Completed

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg (CLARINET FORTE)

Midgut Neuroendocrine Tumours | Pancreatic Tumours

Spain, United Kingdom, Denmark, Belgium, Germany, France, Netherlands, Ireland, Italy, Poland
Ipsen

Completed

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

Acromegaly

Germany, Netherlands, Sweden, Czechia, Denmark, France, Greece, Italy, Spain, United Kingdom
Ipsen

Terminated

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours (SPINET)

Neuroendocrine Tumors in Lung

Canada, United States, Germany, France, United Kingdom, Netherlands, Spain, Denmark, Italy, Austria, Poland
Amine Terzi

Completed

Aromatherapy Massage for Itching Management in Liver Diseases

Liver Diseases | Itching | Massage | Aromatherapy | Skin Moisture | pH Level

Turkey
Ipsen

Completed

Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel (SALSA)

Acromegaly

United States
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

Neuroendocrine Tumours

Spain
Ipsen

Withdrawn

Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice (NETways)

Neuroendocrine Tumors

Poland
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. (ATLANT)

Neuroendocrine Tumours

Italy
Ipsen

Completed

Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel (OPERA)

Neuroendocrine Tumors

France
Ipsen

Terminated

Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment

Thyroid-Associated Ophthalmopathy

Spain
Ipsen

Terminated

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

Malignant Carcinoid Syndrome

United States
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients

Acromegaly

France, Switzerland
Ipsen

Completed

Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly

Acromegaly

Germany
Ipsen

Completed

Somatuline Autogel Preference and Health Economy Study (SAPHE)

Neuroendocrine Tumour With Carcinoid Symptoms

Denmark, Norway, Sweden
Ipsen

Terminated

Quality of Life in Patients With Inoperable Malignant Bowel Obstruction (QoL in IMBO)

Intestinal Obstruction

Italy
Ipsen

Completed

Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

Acromegaly

Australia
Ipsen

Withdrawn

Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

Acromegaly

Mexico
Ipsen

Completed

Somatuline Autogel: Acromegaly Self/Partner Injection Study

Acromegaly

United Kingdom
Ipsen

Completed

Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects (SOMACROL)

Acromegaly

Spain, Portugal
Ipsen

Completed

Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

Acromegaly

United States, Germany, Hong Kong, Czechia, France, Hungary, Netherlands, United Kingdom
Ipsen

Completed

Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients (CALM-NET)

NeuroEndocrine Tumours

United Kingdom
Ipsen

Completed

Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET (SONNET)

Gastroenteropancreatic Neuroendocrine Tumors

Germany, Austria
Ipsen

Completed

Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction (IMIO)

Intestinal Obstruction

Belgium
Ipsen

Completed

Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects (LEAD)

Acromegaly

France, Brazil, Denmark, Finland, Greece, Korea, Republic of, Latvia, Netherlands, Norway, Poland, Romania, Russian Federation, Serbia, Sweden
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly (LANTERN)

Acromegaly

China
Ipsen

Completed

Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly

Acromegaly

Italy
Ipsen

Completed

Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea (MEDARD)

Diarrhea

Belgium
Ipsen

Completed

Somatuline Predictive Factors in Acromegaly and NET (SOPRANo)

Acromegaly | Neuroendocrine Tumours

Switzerland, Austria, Germany
Ipsen

Terminated

Predictive Factors Study (TAPAS)

Acromegaly

Australia
Ipsen

Completed

Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment. (ACRO QLQ)

Acromegaly

Poland
Ipsen

Terminated

A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours (PRELUDE)

Neuroendocrine Tumours

United Kingdom, France, Germany, Australia, Italy
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly (PAOLA)

Acromegaly

United States, Italy, Belgium, Saudi Arabia, Spain, France, Germany, Canada, United Kingdom, Colombia, Brazil, Israel, Turkey, Romania, Norway, Poland, Russian Federation, Argentina
University Medical Center Groningen
Radboud University Medical Center; Erasmus Medical Center; Leiden University...

Unknown

Study of Lanreotide to Treat Polycystic Kidney Disease (DIPAK1)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Netherlands
University Hospital, Ghent
Ipsen

Completed

Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma

Rectal Carcinoma

Belgium
Universitaire Ziekenhuizen KU Leuven
Ipsen

Completed

Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease (LOCKCYST)

Polycystic Liver Disease

Belgium
Universitair Ziekenhuis Brussel

Unknown

Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy

Acid Reflux Esophagitis | Non-acid Reflux Esophagitis

Belgium
American University of Beirut Medical Center

Completed

Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate

Preterm Delivery

Lebanon
Federico II University
Ospedali dei Colli

Completed

GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma (SS-HCC)

Advanced Hepatocellular Carcinoma

Italy
Federico II University
University of Genova

Completed

Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly (ATG1line)

Acromegaly

Italy
Radboud University Medical Center

Unknown

Treatment of the Dumping Syndrome With Lanreotide Autogel®

Dumping Syndrome

Netherlands
Odense University Hospital

Completed

Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction

Acromegaly

Denmark

3

Subscribe